New chemo cocktail aims to boost stem cell transplant success in leukemia

NCT ID NCT07644481

Not yet recruiting Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial is testing a combination of three chemotherapy drugs—clofarabine, busulfan, and melphalan—given before a stem cell transplant in 30 adults with acute myeloid leukemia (AML) who are in first remission. The goal is to see if this conditioning regimen improves survival and reduces the chance of the cancer coming back. Researchers will track outcomes like overall survival and relapse rates over two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Clofarabine, busulfan, and melphalan (chemotherapy drugs)
What this could lead to: If successful, this could offer a more effective conditioning regimen for stem cell transplants in AML, potentially improving long-term survival and reducing relapse.
What could go wrong: This is a small, early-phase study with only 30 participants and no comparison group, so results may not apply broadly. The chemotherapy combination also carries risks like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT AML (ACUTE MYELOGENOUS LEUKEMIA)

More trials for these conditions

Other studies related to the condition(s) this trial covers.